|Title||SARS-CoV-2 vaccine development, access, and equity.|
|Journal Name||J Exp Med|
|Month / Year||01/2021|
|Vol (No)||217 (11)|
Over the past 9 mo, with 34 million infections and 1 million deaths, the COVID-19 pandemic has levied a grisly toll. Some countries, through political will and social organization, have successfully reduced the number of infections and deaths, but the global scale of loss reflects the difficulty of translating these approaches in other countries. An effective SARS-CoV-2 vaccine presents a technological solution to the failure of social and political ones. Vaccines are, however, not a silver bullet, but a safe, cost-effective, and globally applicable tool that will require a substantial effort-cooperation, commitment, time, and funding-to be effective.
|Keyword||Animals; Antibodies, Viral/immunology; Betacoronavirus/*immunology; Biomedical Research/methods; COVID-19; COVID-19 Vaccines; Coronavirus Infections/*immunology/*prevention & control/virology; Host Microbial Interactions/immunology; Humans; *Immunogenicity, Vaccine; Pandemics/*prevention & control; Pneumonia, Viral/*immunology/*prevention & control/virology; SARS-CoV-2; Vaccination; Viral Vaccines/*immunology|